

Table S3. Incidence rates of CIN2+ by HPV genotype among 343 participants followed for up to 5 years, stratified by enrollment histology

HPV genotype ^a	Normal Histology (n=226)				CIN1 (n=117)			
	N	CIN2+ events	Person-months ^b	Incidence rate (95% CI) ^c	N	CIN2+ events	Person-months ^b	Incidence rate (95% CI) ^c
Total HPV-positive	189	12	5294	2.3 (1.3, 4.1)	112	10	2917	3.5 (1.9, 6.5)
High-risk HPV								
Any type	133	10	3707	2.7 (1.5, 5.1)	84	10	2264	4.5 (2.4, 8.4)
16 ^d	21	4	589	7.4 (2.8, 19.8) ^e	15	4	438	9.4 (3.5, 25.0) ^e
18/45 ^d	20	1	664	1.5 (0.2, 10.7)	13	1	356	2.9 (0.4, 20.5)
31/33/35/52/58 ^d	55	4	1476	2.7 (1.0, 7.3)	31	4	781	5.2 (2.0, 14.0)
39/51/56/59/68 ^d	61	4	1663	2.4 (0.9, 6.4)	45	4	1237	3.3 (1.2, 8.8)
18	12	1	420	2.4 (0.3, 17.0)	8	1	213	4.9 (0.7, 34.9)
31	12	0	334	0.0 (0.0, 11.0)	7	1	103	10.2 (1.4, 72.2) ^e
33	5	1	197	5.2 (0.7, 36.6) ^e	3	1	68	16.3 (2.3, 116.0) ^e
35	12	1	284	3.5 (0.5, 25.2)	5	0	117	0.0 (0.0, 31.5)
39	14	1	312	3.2 (0.5, 23.0)	16	2	400	5.1 (1.3, 20.5)
45	8	0	244	0.0 (0.0, 15.1)	5	0	143	0.0 (0.0, 25.8)
51	23	2	646	3.1 (0.8, 12.4)	10	1	272	3.9 (0.5, 27.6)
52	20	2	523	3.9 (1.0, 15.6)	9	1	317	3.2 (0.4, 22.4)
56	9	1	315	3.2 (0.4, 22.7)	10	0	263	0.0 (0.0, 14.0)
58	8	0	195	0.0 (0.0, 18.9)	10	2	224	9.4 (2.3, 37.5) ^e
59	17	0	504	0.0 (0.0, 7.3)	9	1	258	4.0 (0.6, 28.2)
68	6	1	157	6.4 (0.9, 45.4) ^e	10	0	308	0.0 (0.0, 12.0)
Low-risk HPV only	53	2	1558	1.3 (0.3, 5.2)	28	0	652	0.0 (0.0, 5.7)
HPV-negative	37	2	936	2.2 (0.5, 8.6)	5	0	170	0.0 (0.0, 21.7)

^a Includes both single- and multiple-type HPV infections (ie, for multiple types, progression events count towards all individual types present at enrollment)

^b Sum of person-months for all participants in group infected with noted genotype at enrollment; overall median follow-up time per person: 24.3 months

^c Incidence rate per 1000 person-months (95% CI = 95% confidence interval); estimated with exponential accelerated failure time models for interval-censored data; for genotypes with zero events, estimated with Poisson exact method

^d HPV risk stratification groups from Demarco et al. (2020)

^e Highest three incidence rates for an individual HPV genotype among each group